Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $338.7 million.

  • UNITED THERAPEUTICS's Net Income towards Common Stockholders rose 9.58% to $338.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 14.47%. This contributed to the annual value of $1.2 billion for FY2024, which is 21.35% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Net Income towards Common Stockholders of $338.7 million as of Q3 2025, which was up 9.43% from $309.5 million recorded in Q2 2025.
  • Over the past 5 years, UNITED THERAPEUTICS's Net Income towards Common Stockholders peaked at $338.7 million during Q3 2025, and registered a low of $28.3 million during Q1 2021.
  • In the last 3 years, UNITED THERAPEUTICS's Net Income towards Common Stockholders had a median value of $301.3 million in 2024 and averaged $286.4 million.
  • In the last 5 years, UNITED THERAPEUTICS's Net Income towards Common Stockholders tumbled by 79.45% in 2021 and then spiked by 747.70% in 2022.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Net Income towards Common Stockholders stood at $112.2 million in 2021, then climbed by 17.74% to $132.1 million in 2022, then surged by 64.35% to $217.1 million in 2023, then surged by 38.78% to $301.3 million in 2024, then increased by 9.58% to $338.7 million in 2025.
  • Its last three reported values are $338.7 million in Q3 2025, $309.5 million for Q2 2025, and $322.2 million during Q1 2025.